290 related articles for article (PubMed ID: 34128049)
1. High anaphylaxis rates following vaccination with the Pfizer BNT162b2 mRNA vaccine against COVID-19 in Japanese healthcare workers: a secondary analysis of initial post-approval safety data.
Hashimoto T; Ozaki A; Bhandari D; Sawano T; Sah R; Tanimoto T
J Travel Med; 2021 Oct; 28(7):. PubMed ID: 34128049
[No Abstract] [Full Text] [Related]
2. Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers.
Salvagno GL; Henry BM; Pighi L; De Nitto S; Gianfilippi GL; Lippi G
J Infect; 2021 Aug; 83(2):e4-e5. PubMed ID: 34214516
[No Abstract] [Full Text] [Related]
3. [Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers].
Rojkovich B; Németh D; Török E; Szabó B; Pintér Á; Juhász I; Weidl M; Lányi É; Pável-Szecskó J; Lázár I; Perduk A; Reiter J; Nagy G; Nagy E; Géher P
Orv Hetil; 2021 Sep; 162(39):1551-1557. PubMed ID: 34570721
[TBL] [Abstract][Full Text] [Related]
4. Reactogenicity following two doses of the BNT162b2 mRNA COVID-19 vaccine: Real-world evidence from healthcare workers in Japan.
Saita M; Yan Y; Ito K; Sasano H; Seyama K; Naito T
J Infect Chemother; 2022 Jan; 28(1):116-119. PubMed ID: 34580011
[TBL] [Abstract][Full Text] [Related]
5. Relationship between pre-existing allergies and anaphylactic reactions post mRNA COVID-19 vaccine administration.
Desai AP; Desai AP; Loomis GJ
Vaccine; 2021 Jul; 39(32):4407-4409. PubMed ID: 34215453
[TBL] [Abstract][Full Text] [Related]
6. Impaired Humoral Response in Renal Transplant Recipients to SARS-CoV-2 Vaccination with BNT162b2 (Pfizer-BioNTech).
Korth J; Jahn M; Dorsch O; Anastasiou OE; Sorge-Hädicke B; Eisenberger U; Gäckler A; Dittmer U; Witzke O; Wilde B; Dolff S; Kribben A
Viruses; 2021 Apr; 13(5):. PubMed ID: 33923063
[TBL] [Abstract][Full Text] [Related]
7. Pfizer/BioNtech BNT162b2: adverse events and insights from an Australian mass vaccination clinic for COVID-19.
Halder A; Imamura H; Condon S; Boroughs K; Nilsson SC; Anderson T; Caterson ID
Intern Med J; 2022 Jan; 52(1):121-124. PubMed ID: 35060290
[TBL] [Abstract][Full Text] [Related]
8. Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
Iguchi T; Umeda H; Kojima M; Kanno Y; Tanaka Y; Kinoshita N; Sato D
Drug Saf; 2021 Nov; 44(11):1209-1214. PubMed ID: 34347278
[TBL] [Abstract][Full Text] [Related]
9. [Immune thrombocytopenia after BNT162b2 mRNA COVID-19 vaccination].
Matsumura A; Katsuki K; Akimoto M; Sakuma T; Nakajima Y; Miyazaki T; Fujisawa S; Nakajima H
Rinsho Ketsueki; 2021; 62(11):1639-1642. PubMed ID: 34866090
[TBL] [Abstract][Full Text] [Related]
10. The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout.
Zaqout A; Daghfal J; Alaqad I; Hussein SAN; Aldushain A; Almaslamani MA; Abukhattab M; Omrani AS
Int J Infect Dis; 2021 Jul; 108():116-118. PubMed ID: 33992763
[TBL] [Abstract][Full Text] [Related]
11. Hypersensitivity Reactions to Vaccines: Current Evidence and Standards for SARS-CoV-2 Vaccines.
Carvalho JC; Cunha F; Coutinho IA; Loureiro C; Faria E; Bom AT
Acta Med Port; 2021 Jun; 34(7-8):541-547. PubMed ID: 34851819
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
13. Healthcare Staff Perceptions Following Inoculation with the BNT162b2 mRNA COVID-19 Vaccine at University Hospitals Coventry & Warwickshire NHS Trust.
Robbins T; Kyrou I; Clark C; Sharma K; Laird S; Berry L; Morgan N; Patel K; Sankar S; Randeva H
Int J Environ Res Public Health; 2021 Sep; 18(17):. PubMed ID: 34501970
[No Abstract] [Full Text] [Related]
14. Adverse reactions to BNT162b2 mRNA COVID-19 vaccine in medical staff with a history of allergy.
Inoue S; Igarashi A; Morikane K; Hachiya O; Watanabe M; Kakehata S; Sato S; Ueno Y
Respir Investig; 2022 Mar; 60(2):248-255. PubMed ID: 34920980
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
16. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
17. Skin manifestations of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers. 'COVID-arm': a clinical and histological characterization.
Fernandez-Nieto D; Hammerle J; Fernandez-Escribano M; Moreno-Del Real CM; Garcia-Abellas P; Carretero-Barrio I; Solano-Solares E; de-la-Hoz-Caballer B; Jimenez-Cauhe J; Ortega-Quijano D; Fernandez-Guarino M
J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):e425-e427. PubMed ID: 33783873
[No Abstract] [Full Text] [Related]
18. Prevalence of Allergic Reactions After Pfizer-BioNTech COVID-19 Vaccination Among Adults With High Allergy Risk.
Shavit R; Maoz-Segal R; Iancovici-Kidon M; Offengenden I; Haj Yahia S; Machnes Maayan D; Lifshitz-Tunitsky Y; Niznik S; Frizinsky S; Deutch M; Elbaz E; Genaim H; Rahav G; Levy I; Belkin A; Regev-Yochay G; Afek A; Agmon-Levin N
JAMA Netw Open; 2021 Aug; 4(8):e2122255. PubMed ID: 34463744
[TBL] [Abstract][Full Text] [Related]
19. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose.
Chagla Z
Ann Intern Med; 2021 Feb; 174(2):JC15. PubMed ID: 33524290
[TBL] [Abstract][Full Text] [Related]
20. Specialist confirmed allergic reactions to COVID-19 mRNA vaccines at a mass vaccination site.
Myles IA; Vinciguerra JS; Premus RT
Vaccine; 2021 Jul; 39(32):4404-4406. PubMed ID: 34217573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
